Effect of lanreotide autogel/depot (LAN) on tumor growth rate (TGR) in patients with metastatic bronchopulmonary neuroendocrine tumors (BP-NETs): Exploratory data from the phase 3 SPINET study

#3518

Introduction: SPINET (NCT02683941) evaluated LAN in metastatic somatostatin receptor (SSTR)-positive typical and atypical carcinoid (TC and AC) BP-NETs.

Aim(s): To describe SPINET TGR data, a potential biomarker for antitumor drug activity in NETs.

Materials and methods: A phase 3, randomized, double blind (DB), placebo (PBO)-controlled study of LAN (120 mg/28 days), with optional open-label LAN treatment phase (OL LAN). Enrollment was stopped due to slow accrual (planned sample size, 216); ongoing patients in DB phase could transition to OL-LAN. The primary endpoint was centrally assessed (RECIST 1.1) progression free survival (PFS) in the DB/OL-LAN phases in LAN-randomized patients. Centrally-assessed TGR was an exploratory endpoint; baseline TGR was only computed for patients who provided historical scans. TGR was expressed as % increase in target tumor volume per month (M), accounting for change in tumor size (defined as sum of diameters of target lesions).

Conference:

Presenting Author: Capdevila J

Authors: Baudin E, Hörsch D, Singh S, Caplin M, Ferone D,

Keywords: bronchopulmonary neuroendocrine tumor, lanreotide autogel/depot, spinet, tumor growth rate, typical/atypical carcinoid,